Juan Carlos Kaski

Juan Carlos Kaski is an expert in Cardiology at St George's Hospital (United Kingdom, London) (United Kingdom). As of October 2026, ScienceLeadR ranks Juan Carlos Kaski in the top 1% of experts worldwide for Angina Pectoris, Myocardial Ischemia and Coronary Disease. Juan Carlos Kaski has authored 769 publications, the most recent in 2026, and is an investigator in 9 clinical trials, 1 of them ongoing. SLR score: 2,728 (community average: 125). How the SLR is computed.

Cardiology

Subspecialties: Pharmacy - Public Health - Endocrinology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on October 26, 2026

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1984 - 2026

Source: PubMed

St George's Hospital (United Kingdom, London)

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 769

Citations

Citations: 31 514 1st author: 131 Last author: 269 Unique author: 69

Main journals

Eur Heart J 83

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 53

Best Journals

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title	Journal	Year
The Quo Vadis for COVADIS Diagnostic Criteria. PMID 42864254 — cardiovascular diseases	Heart Lung Circ	2026
Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial. PMID 42533000 — prednisolone, biological science disciplines, losartan, therapeutics	Nat Commun	2026
Digital biomarkers in cardiovascular medicine: a scientific statement of the ESC Working Group on e-Cardiology, the ESC Working Group on Cardiovascular Pharmacotherapy, the European Heart Rhythm Association (EHRA) of the ESC, the Association for Acute Cardiovascular Care (ACVC) of the ESC, the Heart Failure Association (HFA) of the ESC, the European Association of Preventive Cardiology (EAPC) of the ESC, the European Association of Cardiovascular Imaging (EACVI) of the ESC, in collaboration with the Digital Cardiology and Artificial Intelligence Committee of the ESC, and the ESC Regulatory Affairs Committee. PMID 42491935 — intelligence, heart failure, heart, drug therapy, cardiology, biomarkers, artificial intelligence, digital biomarkers, digital health	Eur Heart J Digit Health	2026
Cardiovascular prescriber attitudes to pharmacogenomics: a survey by the ESC working group on cardiovascular pharmacotherapy. PMID 42026041 — research design, drug therapy	Pharmacogenomics J	2026
Cardiovascular pharmacotherapy in year in 2025. PMID 41935384 — pharmaceutical preparations, cardiovascular diseases, cardiovascular agents, drug therapy	Eur Heart J Cardiovasc Pharmacother	2026

Clinical Studies 9

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

N/A 3

Phase 3 3

Phase 2 2

Phase 2/Phase 3 1

By status:

Completed 4

Unknown 2

Active not recruiting 1

Recruiting 1

Terminated 1

By type:

Interventional 8

Observational 1

By Monocentric/Multicentric:

monocentric 5

multicentric2to4 1

multicentric5to9 1

multicentricup10 2

Main Topics

Cardiovascular Diseases 8

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study	Phase	Status	Start
Myocardial Protection in Patients With Post acute Inflammatory Cardiac Involvement Due to COVID 19 NCT05619653 — exercise, ventricular remodeling, prednisolone, ventricular dysfunction, microvascular angina, heart, brain, losartan, ventricular dysfunction, left, kidney, pericarditis, signs and symptoms, covid-19, myocarditis, vascular remodeling, therapeutics, infections, acute disease, post-acute covid-19 syndrome	Phase 3	Active not recruiting	2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS

Shopping Cart

System Maintenance Notice